Abstract
Neuroblastoma staging system of The Japanese Society of Pediatric Surgeons (JSPS) was compared to the International Neuroblastoma Staging System (INSS) to clarify its characteristics. Taking into accounl the resectabilily of the primary tumor and having different criteria for lymph node involvement, the INSS substantially differs from the JSPS staging system. To make the results of clinical trials and biological studies that are conducted in our country internationally acceptable, we propose that neuroblastoma patients should be registered according to the INSS in addition to the staging sytem of the ISPS.